TLT

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

Retrieved on: 
Wednesday, January 24, 2024

Professor Philip Bloom, Consultant Ophthalmic Surgeon at Imperial College Healthcare NHS Trust, emphasized the importance of rapid expansion: “We are delighted at Imperial to be able now to offer this minimally invasive treatment for glaucoma.

Key Points: 
  • Professor Philip Bloom, Consultant Ophthalmic Surgeon at Imperial College Healthcare NHS Trust, emphasized the importance of rapid expansion: “We are delighted at Imperial to be able now to offer this minimally invasive treatment for glaucoma.
  • The registry and study is structured for expanded participation from other UK providers to join the program and build enrollment for large patient cohorts.
  • Both Iridex and Imperial College Healthcare NHS Trust are dedicated to conducting this study in accordance with the strictest ethical and regulatory standards and look forward to welcoming additional sites to join the program.
  • Iridex would like to thank and acknowledge Carleton Optical Equipment Ltd, located in Chesham, England, for providing clinical trial training, service, and support.

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

Retrieved on: 
Thursday, December 28, 2023

The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products.

Key Points: 
  • The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products.
  • By retiring the LCDs, the MACs have supported continued access to advanced patient care like MPTLT,” said David I. Bruce, President & CEO, Iridex Corporation.
  • Between October 24th, 2023 and November 9th, 2023, five of the seven MACs published LCDs targeting MIGS procedures, which also partially restricted criteria for coverage of cyclophotocoagulation reimbursement.
  • As a result, there will be no change in January 2024 to the current Medicare coverage for MIGS procedures performed with Iridex MicroPulse® TLT.

Insight Boosts App Solutions Business with Amdaris Acquisition

Retrieved on: 
Thursday, August 17, 2023

Through this acquisition, Insight will add Amdaris’ innovative software development, application support, managed services and consultancy services to its broad solutions portfolio and IT supply chain capabilities.

Key Points: 
  • Through this acquisition, Insight will add Amdaris’ innovative software development, application support, managed services and consultancy services to its broad solutions portfolio and IT supply chain capabilities.
  • Amdaris, a Microsoft-Gold Certified Partner for more than 10 years, has a proven track record of delivering transformative digital journeys.
  • "The acquisition marks an important milestone for Insight as a leading Solutions Integrator,” said Joyce Mullen, president and CEO of Insight.
  • “With the addition of Amdaris, Insight will scale robustly, enhance its technological capabilities, and deliver an even broader range of services and solutions to clients in EMEA.

The Coca-Cola Foundation, Silk, Google, Meta, and Microsoft Fund Longleaf Pine Restoration in East Texas

Retrieved on: 
Tuesday, June 27, 2023

“The Texas Longleaf Team is honored to serve as a conduit for these companies as they seek to achieve their sustainability goals in Southeast Texas,” says Jenny Sanders, Coordinator at Texas Longleaf Team.

Key Points: 
  • “The Texas Longleaf Team is honored to serve as a conduit for these companies as they seek to achieve their sustainability goals in Southeast Texas,” says Jenny Sanders, Coordinator at Texas Longleaf Team.
  • The Texas Longleaf Team was organized in 2010 to promote the restoration of this historic Longleaf Pine ecosystem on private and public forestlands in Southeast Texas.
  • The value of ecosystem forest restoration projects, much like the roots of the longleaf pine, extends beyond just a tree in the ground.
  • Learn more about the longleaf pine on the Texas Longleaf Landscapes Story Map and Texas Longleaf Team website .

Tree Care Marketing Founder Reveals a Simple System to Increase Sales by 30% Overnight

Retrieved on: 
Wednesday, March 8, 2023

EXTON, Pa., March 7, 2023 /PRNewswire/ -- Tree Leads Today (TLT) founder Don Dowd is revealing a simple system that he says can increase tree care sales by 30% overnight. The system involves sending a follow-up letter to homeowners who have received an estimate for the tree care company's services. Dowd refers to this system as "the 60-cent salesperson".

Key Points: 
  • The company's founder, Don Dowd, is sharing a simple strategy that can vastly increase closure rates with minimal time and cost.
  • EXTON, Pa., March 7, 2023 /PRNewswire/ -- Tree Leads Today (TLT) founder Don Dowd is revealing a simple system that he says can increase tree care sales by 30% overnight.
  • The system involves sending a follow-up letter to homeowners who have received an estimate for the tree care company's services.
  • "When I implemented this system in my own tree care company over two decades ago, I saw a 30% increase in sales virtually overnight, and those results are pretty typical.

Iridex Introduces New Research and Showcases Five Events at the AGS Meeting

Retrieved on: 
Thursday, March 2, 2023

MOUNTAIN VIEW, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced Part 2 of the evidence-based guidelines series for MicroPulse Transscleral Laser Therapy (TLT) has been published in Clinical Ophthalmology1 by the international consensus panel of ten glaucoma experts. The publication will be available at booth #5 at the 2023 meeting of the American Glaucoma Society (AGS), March 2 -5 in Austin, Texas.

Key Points: 
  • Watch Dr. Syril Dorairaj’s e-poster on prospective MicroPulse TLT dosimetry research outcomes.
  • The publication will be available at booth #5 at the 2023 meeting of the American Glaucoma Society (AGS), March 2 -5 in Austin, Texas.
  • The Cyclo G6 now provides Sweep Management Software, which allows surgeons to tailor an optimized therapeutic dose for delivering MicroPulse TLT.
  • Demos are available at the Iridex booth where physicians can learn how to improve their surgical technique and consistency in application.

Innovator ETFs Publishes Upside Caps for March Series of Flagship U.S. Equity Buffer ETFs™

Retrieved on: 
Wednesday, March 1, 2023

**“Buffer” refers to the amount of downside protection the fund seeks to provide, before fees and expenses, over the full Outcome Period.

Key Points: 
  • **“Buffer” refers to the amount of downside protection the fund seeks to provide, before fees and expenses, over the full Outcome Period.
  • Outcome Period is the intended length of time over which the defined outcomes are sought.
  • Upon commencement of the Outcome Period, the Caps can be found on a daily basis via www.innovatoretfs.com.
  • The March series of the Innovator U.S. Equity Buffer ETFs™ ( BMAR ; PMAR ; UMAR ) reset annually and can be held indefinitely.

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

Retrieved on: 
Thursday, February 23, 2023

I am encouraged by the positive interim results of the light-activated, intravesical study drug TLD-1433 (Trade Name: Ruvidar) currently under investigation by Theralase® in Study II.

Key Points: 
  • I am encouraged by the positive interim results of the light-activated, intravesical study drug TLD-1433 (Trade Name: Ruvidar) currently under investigation by Theralase® in Study II.
  • The interim analysis of the clinical data collected from Study II to date supports that early results show complete response rates in 53% of patients evaluated at 90 days and 28% of patients evaluated at 450 days.
  • Based on the clinical data presented to date, Rudivar could represent a viable treatment option with an acceptable safety profile.
  • One day we hope that Ruvidar™ will become the organ-sparing solution that is a game-changer for both patients and physicians.”

Innovator ETFs Publishes Upside Cap Ranges for March Series of U.S. Equity Buffer ETFs™

Retrieved on: 
Wednesday, February 22, 2023

The actual Cap for each Fund will be set at the beginning of the Outcome Period, and is dependent upon market conditions at that time.

Key Points: 
  • The actual Cap for each Fund will be set at the beginning of the Outcome Period, and is dependent upon market conditions at that time.
  • As a result, the Cap set by each Fund may be higher or lower than the Estimated Cap Range.
  • **“Buffer” refers to the amount of downside protection the fund seeks to provide, before fees and expenses, over the full Outcome Period.
  • The March series of the Innovator U.S. Equity Buffer ETFs™ ( BMAR ; PMAR ; UMAR ) currently have a remaining outcome period of about one week.

Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company

Retrieved on: 
Tuesday, February 21, 2023

The Venture 50™ is an annual ranking of the top-performing companies from five industry sectors; specifically: Clean Technology and Life Sciences, Diversified Industries, Energy, Mining, and Technology.

Key Points: 
  • The Venture 50™ is an annual ranking of the top-performing companies from five industry sectors; specifically: Clean Technology and Life Sciences, Diversified Industries, Energy, Mining, and Technology.
  • The Venture 50™ ranking is comprised of the top performing companies on the TSX Venture Exchange in 2022, selected based on the equally weighted criteria of: market capitalization, share price appreciation and trading volume.
  • Selected Venture 50™ companies have seen tremendous growth over the past year, offered excellent returns to their shareholders and are actively traded in the market.
  • I am proud to recognize the Theralase® team for their hard work and dedication, and our shareholders for their ongoing support.”